<DOC>
	<DOC>NCT02465645</DOC>
	<brief_summary>After successful screening of patients based on inclusion criteria, we will measure the baseline Hepatic Venous Pressure Gradient. At day 1 patients will undergo complete blood investigation including complete haemogram, kidney function test, liver function test, prothrombin time, AFP (Alfa Feto Protein) level, chest x ray, ultrasonography, fibroscan. Routine complete physical examination will be done.</brief_summary>
	<brief_title>To Compare the Efficacy and Safety of Carvedilol With or Without Simvastatin in Patients With Portal Hypertension and Esophageal Varices.</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Varicose Veins</mesh_term>
	<mesh_term>Hypertension, Portal</mesh_term>
	<mesh_term>Esophageal and Gastric Varices</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>1. All patients of chronic liver disease with esophageal varices. 2. Age more than and equal to 18 years. 1. Patients of chronic liver disease with history of upper Gastro Intestinal bleed. 2. Patients of acute on chronic liver failure 3. Thrombosis of splenoportal axis 4. Hepatocellular carcinoma 5. Patients who were on primary variceal ligation sessions as prophylaxis 6. Patients who are beta blocker intolerant (Prior h/o hypotension, bradycardia). 7. Patients who are contraindicated for beta blockers {H/O COPD (Coronary Obstructive Pulmonary Disease), heart block, refractory Ascites, SBP(Spontaneous Bacterial Peritonitis) , HRS(Hepato Renal Syndrome)}. 8. Failure to give consent for inclusion in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>